60155-63-7

Upstream product

• 155302-28-6 tert.butyl 4-(1H-indol-3-yl)-piperidine-1-carboxylate 
• 155302-27-5 3-[N-(t-butyloxycarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]-1H-indole 
• 17422-32-1 5-chloro-1H-indole 
• 345235-80-5 tert-butyl-4-(5-chloro-1H-indol-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 120-72-9 indole 
• 65347-55-9 3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole 
• 40064-34-4 piperidine-4,4-diol hydrochloride 

Downstream Products

• 1443248-77-8 4-(1H-indol-3-yl)-N-(3-(methylcarbamoyl)phenyl)piperidine-1-carboxamide 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME

A heterocyclic compound represented by formula XI, a pharmaceutically acceptable salt, a solvate, or a solvate of a pharmaceutically acceptable salt thereof, use thereof, and a composition containing the same. The compound is novel in structure and has good STAT5 inhibitory activity.

4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable Stearoyl-CoA desaturase-1 (SCD1) inhibitors. Part 1: Urea-based analogs

A new series of urea-based, 4-bicyclic heteroaryl-piperidine derivatives as potent SCD1 inhibitors is described. The structure-activity relationships focused on bicyclic heteroarenes and aminothiazole-urea portions are discussed. A trend of dose-dependent decrease in body weight gain in diet-induced obese (DIO) mice is also demonstrated.

Synthesis and SAR study of 4-arylpiperidines and 4-aryl-1,2,3,6- tetrahydropyridines as 5-HT2C agonists

A series of substituted 4-arylpiperidines and a smaller family of 4-aryl-1,2,3,6-tetrahydropyridines were synthesized and their biological activity at the 5-HT2C receptor studied to determine whether either series showed noteworthy agonist activity. Structure-activity relationships were developed from the performed receptor binding assays and functional studies, and the results of the analysis are presented herein.

INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

Treatment of depressive states and Parkinson's disease

Novel compositions having antidepressive, antiemetic and anti-Parkinson activities comprising an effective amount of at least one compound selected from the group consisting of 3-(4'-piperidyl)-indoles of the formula SPC1 Wherein R is selected from the group consisting of hydrogen and alkoxy of 1 to 5 carbon atoms and R1 and R2 are individually selected from the group consisting of hydrogen and alkyl of 1 to 5 carbon atoms and their non-toxic, pharmaceutically acceptable acid addition salts and a pharmaceutical carrier and to a method of treating depressive states and Parkinson disease in warm-blooded animals and humans.